Denali Therapeutics Inc (NAS:DNLI)
$ 20.61 -0.71 (-3.33%) Market Cap: 2.97 Bil Enterprise Value: 2.28 Bil PE Ratio: 0 PB Ratio: 2.25 GF Score: 57/100

Denali Therapeutics Inc at Jefferies Healthcare Conference (Virtual) Transcript

Jun 01, 2021 / 02:00PM GMT
Release Date Price: $61.59 (-3.15%)
Michael Yee
Jefferies Financial Group Inc. - Analyst

Hello. Good morning, everyone, and I wanted to welcome you to another great session here at the Jefferies 2021 Global Healthcare Conference. I'm really excited to have Denali with us today, this morning, and particularly, CEO, Ryan Watts, as well as the Chief Medical Officer, Carole Ho. Both of them have been extremely busy, obviously both with pipeline development and clinical studies going on. So, Ryan will kick it off with some brief comments about the overview about all the moving parts at Denali, and we'll certainly have plenty of time and plenty of questions on the table for both of them.

So without further ado, I will kick it over to Ryan just to give a brief overview about all things going on at Denali.

Ryan Watts
Denali Therapeutics Inc. - CEO

Thank you, Mike. Thank you for the invitation and good morning. Very excited to get into the questions. So I thought I would just spend a few minutes to tell you -- everyone where we are at Denali and a reminder of why we built Denali to begin with,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot